Arete Wealth Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Arete Wealth Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,050	Closed	-$36K	–	773
2023 Q1	$36K	Hold	14,050	–	–	﹤0.01%	629
2022 Q4	$26.3M	Buy	+14,050	New	+$35K	﹤0.01%	611

Other funds holding PRTK

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Arete Wealth Advisors's PRTK Position: Q2 2023 in Review

Arete Wealth Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 14,050 shares — an estimated $36K sold.

Arete Wealth Advisors first reported a position in PRTK in Q4 2022 and held it in 2 quarters. The position peaked at $26.3M in Q4 2022. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Arete Wealth Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Arete Wealth Advisors sold 14,050 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $36K.
Arete Wealth Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
Arete Wealth Advisors's Paratek Pharmaceuticals, Inc. position peaked at $26.3M in Q4 2022.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Arete Wealth Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.